Skip to main content

Epidauros Licenses Drug Metabolism Biomarker to Osmetech to Push Into PGx

NEW YORK (GenomeWeb News) — Osmetech will use Epidauros Biotechnologies’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing, the companies said today.
The diagnostic healthcare company has signed a non-exclusive licensing agreement to use the IP to the genetic variant 2988G>A, which it will use in combination with other variants as predictive markers in its molecular and critical care diagnostic ventures.
Financial details were not disclosed.
Epidauros, a German pharmacogenomics services company, entered into a similar licensing agreement with the same biomarker with Bioscience Corp this spring for services concerning. That deal included an up-front signing fee and royalties.  
Osmetech, based in Pasadena, Calif., currently has a cystic fibrosis product on the market and plans to make its e-Sensor platform its first entry into pharmacogenomics.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.